HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. We have established a service system formulated as "1+2+3+4=1" and can supply original factory goods of well-known brands for P29, the core intermediate of semaglutide.
As an R&D-oriented foreign trade service provider, HiSiaddi has repeatedly proposed formulation optimization schemes and application improvement suggestions for P29 by leveraging technological transformation cooperation with manufacturers and precise insight into market demands. Below is the technical consultation case of HiSiaddi regarding formulation optimization of P29.
For further formulation optimization consultation services, please contact HiSiaddi customer service.
The client is Novo Pharma DK, a high-end pharmaceutical enterprise headquartered in Copenhagen, Denmark, specializing in the R&D and commercial production of GLP-1 innovative drugs with products covering high-end pharmaceutical markets across Europe and North America. The company strictly complies with FDA, EMA, ICH Q7a and GMP quality management specifications. As the core intermediate for synthesizing semaglutide API, P29 (29-peptide) has an annual procurement volume of 180 kg for multiple commercial production lines, making it a typical high-end overseas pharmaceutical client.
The client previously sourced imported P29 long-term. To optimize supply chain structure and control overall costs, it shifted to domestic high-purity P29 intermediates. After material feeding, the efficiency of downstream condensation coupling reactions decreased, impurities in finished API exceeded standards, and batch stability of workshop production deteriorated, driving down yield rates of multiple production lines continuously. The client’s internal R&D and production teams adjusted formulation recipes and production parameters multiple times yet failed to eradicate the issues, risking delays in new drug and conventional pharmaceutical deliveries. The client then entrusted HiSiaddi to fully trace root causes and deliver actionable technical solutions.
HiSiaddi assembled a biopharmaceutical technical team, collaborated with technical personnel from domestic suppliers, and conducted full-process traceability analysis combining the client’s formulation system, workshop production conditions and P29 raw material test data, identifying four core issues and their root causes:
1.
Insufficient reaction activity of downstream coupling formulation leading to reduced synthetic yield When coupling P29 with side-chain fragments via liquid-phase condensation, the actual conversion rate dropped by 11% compared with imported raw materials, accompanied by a sharp rise in by-products. Root cause: Slightly elevated truncated peptides and degraded peptide impurities in P29 batches occupy active reaction sites and inhibit condensation reactions. Trace buffer salts adsorbed on raw material surfaces alter the ionic strength of the reaction system and disrupt the original pH balance of the formulation.
2.
3.
Excessive related substances in finished semaglutide API failing pharmacopoeia testing Single and total impurities in final semaglutide API exceeded EMA pharmacopoeia limits, blocking entry to subsequent formulation processes. Root cause: Minor oxidative degradation of peptide chains occurs during P29 storage and feeding, with degradation products carried into downstream processes. Residual trace proteases in raw materials continuously trigger peptide chain cleavage and generate new impurities.
4.
5.
Flocculent agglomeration and uneven suspension during dissolution and preparation Visible flocculent agglomerates form when dissolving P29 lyophilized powder per the original ratio, which cannot be fully dispersed even with extended stirring, increasing filtration load and material loss. Root cause: Hydrophobic groups exist on P29 peptide chains; mismatched lyophilization curve parameters encourage molecular aggregation. The client’s original dissolution solvent ratio fails to match domestic raw material properties with poor polarity compatibility, exacerbating agglomeration.
6.
7.
Fluctuating material performance across batches hindering standardized production line control Different P29 batches require repeated adjustments to reaction temperature, pH and feeding ratios, preventing standardized production parameter locking and increasing production management difficulty. Root cause: Domestic manufacturers adopt wide control ranges for critical indicators including moisture and residual solvents across batches, leading to inconsistent batch performance. The client lacks differentiated incoming inspection and process adaptation standards tailored to domestic raw materials.
8.
Combining polypeptide intermediate characteristics and the client’s complete production chain, HiSiaddi developed phased rectification plans covering raw material quality upgrading, downstream formulation optimization, production process adjustment and storage & usage specifications, with full-process verification completed within 20 days.
Cooperate with domestic partner manufacturers to upgrade P29 refining and post-treatment workflows:
1. Optimize multi-step chromatography purification to enhance separation of truncated and degraded peptides, controlling single heteropeptide content below 0.08% and total impurities strictly under 0.4%.
2. Add desalination and low-temperature vacuum desolvation steps to fully remove residual buffer salts and organic solvents and eliminate ionic interference in reaction systems.
3. Adjust lyophilization curves with gradient cooling and low-temperature sublimation to reduce peptide molecular aggregation risks, inactivate residual proteases and prevent subsequent degradation.
4. Unify internal control indicators across batches by narrowing control ranges for moisture, residual solvents and other key parameters to guarantee batch consistency.
Based on physicochemical properties of rectified P29, fine-tune the condensation reaction system without altering the client’s core production process:
1. Slightly adjust solvent ratios to boost system polarity and improve mutual solubility between P29 and reactive fragments.
2. Precisely fine-tune initial system pH to match the activity range of domestic raw materials and restore standard condensation efficiency.
3. Optimize catalyst dosage and feeding timing to offset negative impacts from trace impurities and suppress side reactions.
1. Optimize pre-dissolution workflow: Adopt low-temperature segmented stirring (low-speed infiltration first, followed by high-speed dispersion) to avoid agglomeration from rapid one-time feeding.
2. Add a small amount of solubilizing additives to optimize dissolution systems and break hydrophobic peptide aggregation structures for fully transparent and homogeneous solutions.
3. Refine filtration grades with matched pore-size filter cartridges to intercept trace agglomerates and guarantee clean feed liquid.
1. Storage control: Mandate sealed -20°C refrigeration for all P29 batches, minimize open exposure at ambient temperature and adopt light-shielded packaging to prevent peptide chain oxidative degradation.
2. Incoming inspection: Assist the client in establishing special incoming test items for domestic P29 focusing on heteropeptides, moisture and protease activity to screen abnormal batches in advance.
3. Process standardization: Lock a universal set of production parameters based on stabilized raw material indicators to eliminate repeated cross-batch process adjustments.
HiSiaddi assigns dedicated technical specialists to liaise with the client’s R&D and production departments, synchronizing full test reports for every batch of raw materials. Real-time technical support and regular process review optimization are provided for new issues arising during production.
· Condensation reaction conversion rate restored to standard levels with drastically reduced by-products and normalized synthetic yield.
· All related substance indicators of API meet EMA and FDA pharmacopoeia requirements, passing testing smoothly.
· Zero material agglomeration during dissolution, 6% reduction in filtration loss and improved preparation efficiency.
· Stabilized cross-batch material performance enabling standardized production line parameters and greatly reduced production management difficulty.
Production yield rebounded from 87% pre-rectification to over 99%, fully resolving production capacity constraints and enabling the client to fulfill global order deliveries on schedule. Supported by domestic raw materials and process optimization, the client’s overall production cost decreased by 28% compared with the original imported material solution.
The client’s technical director stated: "HiSiaddi accurately identified hidden technical problems and delivered actionable optimization schemes aligned with raw material characteristics and actual production conditions, balancing quality, efficiency and cost, fully meeting the technical service standards of high-end pharmaceutical enterprises."
Both parties renewed a three-year annual procurement agreement with annual P29 procurement volume raised to 220 kg. The client further entrusted HiSiaddi with procurement and technical services for other peptide intermediates and protected amino acids in the semaglutide series, forming an in-depth strategic partnership.
For overseas high-end pharmaceutical manufacturers utilizing core polypeptide intermediates such as P29, heteropeptides, residual salts, active proteases, lyophilized morphology and batch variations in raw materials will trigger cascading issues including abnormal downstream formulation reactions, excessive finished product impurities and difficult material processing. Most raw material suppliers only focus on factory-release indicators and lack understanding of downstream pharmaceutical manufacturing workflows, making them unable to deliver full-process technical support.
Leveraging professional knowledge of polypeptide raw materials and downstream pharmaceutical application experience, HiSiaddi traces root causes at the raw material end, optimizes formulation workflows and standardizes production processes to resolve full-chain technical bottlenecks in one stop. This stabilizes high-end pharmaceutical production lines, guarantees compliance and on-time delivery for clients, and secures trust from overseas high-end pharmaceutical enterprises through robust technical service capabilities, supporting continuous penetration of high-end domestic pharmaceutical intermediates into the global high-end pharmaceutical market.
For further formulation optimization consultation services, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
